Beta Blockers No Benefit After Heart Attack; Women Risk — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- REBOOT Trial enrolled 8,505 patients from 109 Spanish and Italian hospitals, randomly assigning them to beta‑blocker therapy or no beta‑blocker after an uncomplicated heart attack, with a median follow‑up of nearly four years.
- Beta blockers showed no statistically significant reduction in all‑cause mortality, recurrent myocardial infarction, or heart‑failure hospitalization among patients whose left‑ventricular function remained normal.
- Women on beta‑blocker therapy experienced a higher incidence of death, repeat heart attack, or heart‑failure admission than women who did not receive the drug.
- Valentin Fuster presented the trial’s findings at the European Society of Cardiology Congress in Madrid, and the data were published in The New England Journal of Medicine.
- International clinical guidelines are expected to be revised, as the trial challenges a four‑decade‑old standard of post‑myocardial infarction care.
Why it matters: Patients and health systems stand to save on unnecessary medication for the 8,505 trial participants and millions worldwide, while clinicians must adjust prescriptions to avoid heightened risk for women.
Ask SkimNews
